ADMS - Adamas Pharmaceuticals Inc (Healthcare: Drug Manufacturers - Specialty & Generic) Projected Earnings Date: 2022-05-27    (Delayed quote data   )
Last
 		 Change
 ⇓ 0.00   (%)		 Volume
  0
Open
 		 High
 		 Low
 
8EMA (Daily)
 0.00		 40EMA (Daily)
 		 50EMA (Daily)
 		 STO (Daily)
 		 MACD Hist (Daily)
 
8EMA (Weekly)
 7.579		 40EMA (Weekly)
 5.83		 50EMA (Weekly)
 5.65		 STO (Weekly)
 98.897		 MACD Hist (Weekly)
 0.606
Company Profile
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com